Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.
Thomas DeckerMatthias ZaissDunja KleinAntje HahnVolker HagenPaul La RoséeRüdiger LierschThomas WolffBeate NiemeierLarissa E HillebrandCarolin LennartzMarco ChiabudiniFee BengschMartin IndorfNorbert MarschnerPublished in: Breast care (Basel, Switzerland) (2023)
Treatment of patients with visceral metastatic HR-positive, HER2-negative BC with ribociclib in combination with ET showed a tendency toward a more favorable clinical outcome. Despite small numbers of patients and sites, this head-to-head comparison with chemotherapy supports the use of ribociclib with ET in patients with visceral metastasis at risk of fast disease progression.
Keyphrases
- phase iii
- end stage renal disease
- newly diagnosed
- insulin resistance
- ejection fraction
- clinical trial
- open label
- squamous cell carcinoma
- chronic kidney disease
- locally advanced
- small cell lung cancer
- optic nerve
- prognostic factors
- stem cells
- young adults
- randomized controlled trial
- optical coherence tomography
- chemotherapy induced